A bioinformatics analysis of the clinicopathological and prognostic significance of FAM64A mRNA expression in gynecological cancers

References

• Aquil, A., et al., 2021. Predictors of mental health disorders in women with breast and gynecological cancer after radical surgery: a cross-sectional study. Annals of Medicine and Surgery, 65, 102278.
   PubMed Web of Science ®Google Scholar
• Archangelo, L.F., et al., 2013. The CATS (FAM64A) protein is a substrate of the kinase interacting stathmin (KIS). Biochimica et Biophysica Acta, 1833 (5), 1269–1279.
   PubMed Web of Science ®Google Scholar
• Barbutti, I., et al., 2016. CATS(FAM64A) abnormal expression reduces clonogenicity of hematopoietic cells. Oncotarget, 7 (42), 68385–68396.
   PubMedGoogle Scholar
• Di Donato, V., et al., 2023. Recent advances in endometrial cancer management. Journal of Clinical Medicine, 12 (6), 2241.
   PubMed Web of Science ®Google Scholar
• Fu, M., et al., 2023. Cell cycle-related FAM64A could be activated by TGF-β signaling to promote glioma progression. Cellular and Molecular Neurobiology, in press. DOI: 10.1007/s10571-023-01348-2.
   Web of Science ®Google Scholar
• Giannini, A., et al., 2022. Advances on prevention and screening of gynecologic tumors: Are we stepping forward? Healthcare, 10 (9), 1605.
   Web of Science ®Google Scholar
• Golia D’Augè, T., et al., 2023. Novel insights into molecular mechanisms of endometrial diseases. Biomolecules, 13 (3), 499.
   PubMed Web of Science ®Google Scholar
• Hussein, Y.R., et al., 2015. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Modern Pathology, 28 (4), 505–514.
   PubMed Web of Science ®Google Scholar
• Hashimoto, K., et al., 2017. FAM64A is a novel cell cycle promoter of hypoxic fetal cardiomyocytes in mice. Scientific Reports, 7 (1), 4486.
   PubMedGoogle Scholar
• Jiang, F., et al., 2021. High expression of PIMREG predicts poor survival outcomes and is correlated with immune infiltrates in lung adenocarcinoma. PeerJ, 9, e11697.
   PubMed Web of Science ®Google Scholar
• Jiang, L., et al., 2019. Overexpression of PIMREG promotes breast cancer aggressiveness via constitutive activation of NF-κB signaling. EBioMedicine, 43, 188–200.
   PubMed Web of Science ®Google Scholar
• Jiang, Y., et al., 2020a. FAM64A promotes osteosarcoma cell growth and metastasis and is mediated by miR-493. Journal of Oncology, 2020, 2518297.
   PubMed Web of Science ®Google Scholar
• Jiao, Y., et al., 2019. Aberrant FAM64A mRNA expression is an independent predictor of poor survival in pancreatic cancer. PLoS One, 14 (1), e0211291.
   PubMed Web of Science ®Google Scholar
• Jiang, Z.M., et al., 2020b. PIMREG, a marker of proliferation, facilitates aggressive development of cholangiocarcinoma cells partly through regulating cell cycle-related markers. Technology in Cancer Research & Treatment, 19, 1533033820979681.
   Web of Science ®Google Scholar
• Little, J., et al., 2009. STrengthening the REporting of Genetic Association Studies (STREGA)–an extension of the STROBE statement. Genetic Epidemiology, 33 (7), 581–598.
   PubMed Web of Science ®Google Scholar
• Oaknin, A., et al., 2022. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. Journal for ImmunoTherapy of Cancer, 10 (1), e003777.
   PubMed Web of Science ®Google Scholar
• Paepke, D., et al., 2020. Prevalence and predictors for nonuse of complementary medicine among breast and gynecological cancer patients. Breast Care, 15 (4), 380–385.
   PubMed Web of Science ®Google Scholar
• Qiu, X., et al., 2021. FAM64A antagonizes tumor suppressive effects of miR-610 in neuroblastoma in vitro. Journal of Neurosurgical Sciences, 2021, 9.
   Google Scholar
• Segev, Y., et al., 2021. Correlation between an integrative oncology treatment program and survival in patients with advanced gynecological cancer. Supportive Care in Cancer, 29 (7), 4055–4064.
   PubMed Web of Science ®Google Scholar
• Seland, M., et al., 2022. Distress, problems and unmet rehabilitation needs after treatment for gynecological cancer. Acta Obstetricia et Gynecologica Scandinavica, 101 (3), 313–322.
   PubMed Web of Science ®Google Scholar
• Vargiu, V., et al., 2022. Impact of obesity on sentinel lymph node mapping in patients with apparent early-stage endometrial cancer: the ObeLyX study. Gynecologic Oncology, 165 (2), 215–222.
   PubMed Web of Science ®Google Scholar
• Wang, D., et al., 2021a. Tumor-promoting function of PIMREG in glioma by activating the β-catenin pathway. Biotech, 11 (8), 380.
   Google Scholar
• Wang, L., et al., 2021b. Identification of immune-related therapeutically relevant biomarkers in breast cancer and breast cancer stem cells by transcriptome-wide analysis: a clinical prospective study. Frontiers in Oncology, 10, 554138.
   PubMed Web of Science ®Google Scholar
• Xu, Z.S., et al., 2019. FAM64A positively regulates STAT3 activity to promote Th17 differentiation and colitis-associated carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America, 116 (21), 10447–10452.
   PubMed Web of Science ®Google Scholar
• Yao, H., et al., 2023. PIMREG is a prognostic biomarker involved in immune microenvironment of clear cell renal cell carcinoma and associated with the transition from G1 phase to S phase. Frontiers in Oncology, 13, 1035321.
   PubMed Web of Science ®Google Scholar
• Yao, Z., et al., 2019. Knockdown of FAM64A suppresses proliferation and migration of breast cancer cells. Breast Cancer, 26 (6), 835–845.
   PubMed Web of Science ®Google Scholar
• Zhang, J., et al., 2019. Up-regulation of FAM64A promotes epithelial-to-mesenchymal transition and enhances stemness features in breast cancer cells. Biochemical and Biophysical Research Communications, 513 (2), 472–478.
   PubMed Web of Science ®Google Scholar
• Zhang, X., et al., 2022. PICALM exerts a role in promoting CRC progression through ERK/MAPK signaling pathway. Cancer Cell International, 22 (1), 178.
   PubMed Web of Science ®Google Scholar
• Zhao, X., et al., 2022. FAM64A promotes HNSCC tumorigenesis by mediating transcriptional autoregulation of FOXM1. International Journal of Oral Science, 14 (1), 25.
   PubMed Web of Science ®Google Scholar
• Zhao, W.M., et al., 2008. RCS1, a substrate of APC/C, controls the metaphase to anaphase transition. Proceedings of the National Academy of Sciences of the United States of America, 105 (36), 13415–13420.
   PubMed Web of Science ®Google Scholar
• Zheng, H.C., et al., 2023. The bioinformatics analysis about the clinicopathological and prognostic significances of oocyte-arresting BTG4 mRNA in gynecological cancers. Journal of Obstetrics and Gynaecology, 43 (1), 2182672.
   Web of Science ®Google Scholar
• Zhou, Y., et al., 2021. FAM64A is an androgen receptor-regulated feedback tumor promoter in prostate cancer. Cell Death & Disease, 12 (7), 668.
   PubMed Web of Science ®Google Scholar
• Zhu, H., et al., 2022. Predictive value of PIMREG in the prognosis and response to immune checkpoint blockade of glioma patients. Frontiers in Immunology, 13, 946692.
   PubMedGoogle Scholar
• Zhu, H., et al., 2021. Pan-cancer analysis of PIMREG as a biomarker for the prognostic and immunological role. Frontiers in Genetics, 12, 687778.
   PubMed Web of Science ®Google Scholar